A new approach to the management of ovarian endometrioma to prevent tissue damage and recurrence

Giuseppe Benagiano, Benagiano G, Felice Petraglia, Stephan Gordts, Gordts S, Ivo Brosens, Brosens I
Reproductive biomedicine online · 2016 · vol. 32(6) , pp. 556–562 · doi:10.1016/j.rbmo.2016.03.001 · PMID:27037156 · W2294939295
review OA: bronze CC0 ⤵ 13 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper introduces a novel management strategy for ovarian endometriomas aimed at preventing both tissue damage and future recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Management of ovarian endometrioma is a matter of debate between those advocating early treatment and those believing that cysts less than 3 cm in diameter should not be submitted to surgery. To explore a new approach to its management capable of preserving future fertility, the molecular pathology of ovarian endometrioma is reviewed and mechanisms by which the endometrioma progressively affects the ovary during reproductive life are summarized. The scope of new therapeutic modalities includes restoring the progesterone receptor ratio using progestin or progesterone receptor modulators and decreasing local oestrogen production through an aromatase inhibitor. In addition, free radical production can be blocked by antioxidants and the autophagic process by increasing apoptosis. Finally, metalloproteinases and relaxin activity, as well as the inflammatory process can be controlled. Many of these pharmacological treatments lend themselves to local administration and can be applied through intracystic drug administration; in fact, the intracystic route has already been tried with recombinant interleukin-2, methotrexate and ethanol; the latter to obtain sclerotization. Specifically, it is proposed that endometrial growth in the endometrioma is suppressed by intra-cystic application of synthetic progestins, such as levonorgestrel or danazol, selective progesterone receptor modulators, such as mifepristone, ulipristal or asoprisnil, without affecting ovarian activity.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Endometriosis Ovarian Diseases Adolescent Adult Animals Apoptosis Aromatase Inhibitors Aromatase Inhibitors Endometriosis Endometrium Endometrium Estrogens Estrogens Ethanol Ethanol Female Fertility Preservation Free Radicals Free Radicals Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (67)

Cited by (13)

SciLite annotations

chemicals 9
progestin estrogen methotrexate ethanol progestin levonorgestrel danazol mifepristone ulipristal

Source provenance

europepmc
last seen: 2026-07-26T06:08:39.051465+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:07.355239+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
License: CC0 · commercial use OK